Storia in 5 fonti

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

Raccontata da

morningstar.com

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo1 mese fa

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

originale

Timeline cronologica

lunedì 8 giugno 2026·morningstar.com
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
martedì 9 giugno 2026·biopharmadive.com
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.

benzinga.com

1 mese fa

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial - Gilead Sciences (NASDAQ:GILD), Merck & Co (NYS

Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda Combination Ends

Leggi questa versione → originale

fiercepharma.com1 mese fa

As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals

Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer (NSCLC) has narrowed. | Merck & Co. and…

Leggi questa versione → originale

endpoints.news1 mese fa

Trodelvy misses again in lung cancer, but Gilead and Merck have an HIV success to soften the blow

Gilead and Merck end EVOKE-03 Trodelvy-Keytruda lung cancer study after missing PFS endpoint; oral lenacapavir-islatravir HIV combo hits primary endpoint in two Phase 3 trials.

Leggi questa versione → originale

biopharmadive.com1 mese fa

Merck, Gilead report mixed outcomes in key lung cancer, HIV studies

Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.

Leggi questa versione → originale

martedì 9 giugno 2026·

endpoints.news

Trodelvy misses again in lung cancer, but Gilead and Merck have an HIV success to soften the blow

Gilead and Merck end EVOKE-03 Trodelvy-Keytruda lung cancer study after missing PFS endpoint; oral lenacapavir-islatravir HIV combo hits primary endpoint in two Phase 3 trials.

martedì 9 giugno 2026·

fiercepharma.com

As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals

Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer…

martedì 9 giugno 2026·

benzinga.com

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial - Gilead Sciences (NASDAQ:GILD), Merck & Co (NYS

Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda Combination Ends